论文部分内容阅读
色甘酸二钠(disodium cromoglycate)是七十年代初期合成的一种肥大细胞脱粒抑制剂,我国自1972年起在天津、上海先后研制,目前已有供应。该药主要用于各种类型的哮喘,特别是过敏性哮喘。有关该药的作用原理虽有不少争论,但一般认为其作用发生在抗原和抗体结合之后,为保持肥大细胞暂时稳定而不释放体液介质,从而减轻抗原-抗体反应的损害。色甘酸二钠不和IgE结合,也不影响IgE附着于肥大细胞,更不干扰过敏原和IgE在肥大细胞表面的结合。至于该药稳定肥大细胞的机理,可能与抑制钙离子进入细胞有关,因为
Disodium cromoglycate is a mast cell degranulation inhibitor synthesized in the early seventies. Since 1972, it has been developed in Tianjin and Shanghai and is currently available. This medicine is mainly used for various types of asthma, especially allergic asthma. Although there are many controversies about the principle of action of the drug, it is generally believed that its action occurs after antigen and antibody are combined, so as to keep the mast cells temporarily stable and not release the body fluid medium, thereby alleviating the damage of the antigen-antibody reaction. Disodium cromolyn does not bind to IgE, nor does it affect IgE attachment to mast cells, nor does it interfere with the binding of allergens and IgE to mast cells. As for the mechanism of stabilizing mast cells, it may be related to inhibiting the entry of calcium ions into the cells because